Lynne Lederman, PhD
Published Online: Sunday, Jun 18, 2017.
“The single agent has some activity; 50% of patients have some response. The response even as a single agent is quite durable, which is reassuring,” said lead author Martin David Forster, MD, PhD, of University College London Hospitals in the United Kingdom.
“The other standout point is the combination with doxorubicin is really quite impressive in response rate and durability of response...